Why Scientists Are Revisiting a Polarizer - Scorecard - MDSpire

Why Scientists Are Revisiting a Polarizer

The nation’s top cancer institute takes a closer look at a disputed drug.

  • By

  • Rachana Pradhan

  • February 10, 2026

  • 8 min

Share

Clinical Scorecard: Why Scientists Are Revisiting a Polarizer

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationCancer patients, particularly those influenced by misinformation and social media narratives.
Care Setting

Key Highlights

  • NCI is studying ivermectin as a potential cancer treatment despite lack of evidence and new data.

Guideline-Based Recommendations

Diagnosis

    Management

    • Monitor patients for misinformation regarding ivermectin's efficacy.
    • Discourage the use of ivermectin for cancer treatment due to lack of evidence.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Patients with cancer, particularly those influenced by social media narratives.

        No evidence supports ivermectin's safety or efficacy in treating cancer.

        Clinical Best Practices

        • Educate patients about the lack of evidence for ivermectin in cancer treatment.
        • Encourage patients to adhere to proven cancer therapies.
        • Monitor for adverse effects in patients using ivermectin.
        • Discuss the risks associated with ivermectin use.

        Related Resources & Content

        Original Source(s)

        Why Scientists Are Revisiting a Polarizer

        • by Rachana Pradhan

        • February 10, 2026

        Related Content

        FDA Names PreCheck Participants

        Seven companies will participate in a two-phase program that provides early FDA technical guidance during development of new US pharmaceutical manufacturing facilities.

        Hemodynamic Instability in Intubation May Be Predictable

        Narrative review describes how physiologic stressors accumulate from induction through postintubation care and may contribute to cardiovascular deterioration during airway management.

        FDA Approves Treg Cell Therapy

        A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.